Glucocorticoid-induced remission in patients with IgG4-RD is associated with a decrease of circulating CD4+ CTLs, a recently identified potentially pathogenic population of T lymphocytes (49). Here, CD4 is linked to immunoglobulin G4-related sclerosing disease.